The impact of experimental design on assessing mechanism-based inactivation of CYP2D6 by MDMA (Ecstasy)

Author:

Van Linh M.,Heydari Amir1,Yang Jiansong2,Hargreaves Judith3,Rowland-Yeo Karen2,Lennard Martin S.1,Tucker Geoffrey T.,Rostami-Hodjegan Amin4

Affiliation:

1. Academic Unit of Clinical Pharmacology, University of Sheffield, Pharmacokinetics and Pharmacogenetics Group, Division of Clinical Sciences (South), Sheffield, UK

2. Simcyp Ltd, Blades Enterprise Centre, Sheffield, UK

3. AstraZeneca, DMPK, Macclesfield, Cheshire, UK

4. Academic Unit of Clinical Pharmacology, University of Sheffield, Pharmacokinetics and Pharmacogenetics Group, Division of Clinical Sciences (South), and Simcyp Ltd, Blades Enterprise Centre, Sheffield, UK

Abstract

MDMA (3-4-methylenedioxymethamphetamine, commonly known as Ecstasy) is a potent mechanism-based inhibitor (MBI) of cytochrome P450 2D6 (CYP2D6), causing quasi-irreversible inhibition of the enzyme in vitro. An evaluation of the in vivo implications of this phenomenon depends on the accuracy of the estimates of the parameters that define the inhibition in vitro, namely kinact (the maximal inhibition rate) and KI (the inactivation constant). These values are determined in two steps, pre-incubation of the enzyme with the inhibitor (enzyme inactivation), followed by dilution and further incubation to measure residual enzyme activity with a probe substrate. The aim of this study was to assess the impact of different dilutions and probe substrate concentrations on the estimates of kinact and KI using recombinantly expressed CYP2D6. Enzyme activity was measured by the conversion of dextromethorphan (DEX) to dextrorphan (DOR). Dilution factors of 1.25, 2, 5, 10, 25 and 50 (DEX at 30µM) gave mean (±SE) values of kinact (min 1) of 0.20±0.06, 0.21±0.05, 0.31±0.06, 0.37±0.11, 0.51±0.10 and 0.58±0.08, respectively, and KI (µM) values (after correction for non-specific microsomal binding) of 2.22±1.90, 2.80±1.34, 5.78±2.07, 6.36±2.93, 3.99±1.57 and 4.86±1.37, respectively. Accordingly, high (e.g. 50 fold) and low (e.g. 1.25 fold) dilutions were associated with statistically significant differences in kinetic values ( p <0.05). Varying DEX concentration (10–100µM) was not associated with significant changes in kinact and K values when a five-fold dilution was used (with the exception of a lower KI at 10µM DEX). High dilution was also shown to reduce non-specific microsomal binding of MDMA. The changes in the two kinetic parameters were dependent on the experimental procedure and shown to be unlikely to have a material influence on the maximum inhibition of CYP2D6 expected in vivo after typical recreational doses of MDMA (50–100mg), since the potency of inhibition was high. The different values of the kinetic parameters were predicted to have a marginal influence on the time for recovery of enzyme activity following re-synthesis of CYP2D6.

Publisher

SAGE Publications

Subject

Pharmacology (medical),Psychiatry and Mental health,Pharmacology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3